Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2015 | Editorial Commentary

Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer

Authors: David Groheux, Elif Hindié

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2015

Excerpt

In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, García Vicente and colleagues report on the role of ¹⁸F-FDG PET/CT in patients with clinical stage II or III breast cancer (BC). Following PET/CT imaging, the new metabolic stage was stage IV in 38 out of 198 patients (19 %). This had a major prognostic impact. The hazard ratio for death from BC (overall survival) was 0.117 for stage II vs. metabolic stage IV and 0.28 for stage III vs. metabolic stage IV [1]. Although the title of the study refers to locally advanced BC, about half of the included patients had clinical stage II disease [1]. Locally advanced BC is variably defined in the literature; some recommendations such as that of the National Comprehensive Cancer Network refers to patients with N2, N3 or T4 disease, i.e. AJCC clinical stages IIIA (excluding T3N1), IIIB and IIIC (Table 1) [2, 3].

Table 1

TNM stage grouping for breast cancer according to the AJCC Cancer Staging Manual [3]

AJCC stage	TNM			NCCN
I	T1	N0	M0	Primary operable breast cancer
IIA	T0	N1	M0
	T1	N1	M0
	T2	N0	M0
IIB	T2	N1	M0
IIB	T3	N0	M0
IIIA	T3	N1	M0
	T0	N2	M0	Locally advanced breast cancer
	T1	N2	M0
	T2	N2	M0
	T3	N2	M0
IIIB	T4	N0	M0
	T4	N1	M0
	T4	N2	M0
IIIC	Any T	N3	M0
IV	Any T	Any N	M1	Metastatic disease

AJCC American Joint Committee on Cancer, TNM Tumor Nodes Metastasis classification, NCCN National Comprehensive Cancer Network

…

García Vicente A, Soriano Castrejón Á, López-Fidalgo J, Amo-Salas M, del Muñoz Sánchez M, Álvarez M, et al. Basal 18F-FDG PET/CT as a prognostic biomarker in patients with locally advanced breast cancer. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3102-x.PubMed

NCCN. Clinical Practice Guidelines in Oncology: breast cancer, version 2. Fort Washington, PA: National Comprehensive Cancer Network; 2015. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed

Cochet A, Dygai-Cochet I, Riedinger J-M, Humbert O, Berriolo-Riedinger A, Toubeau M, et al. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428–37.CrossRefPubMed

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy A-S, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.PubMedCentralCrossRefPubMed

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578–83.PubMedCentralCrossRefPubMed

Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617–24.CrossRefPubMed

Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRefPubMed

Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3110-x

10.

Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416–27.CrossRefPubMed

11.

Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, et al. Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150:209–17.PubMedCentralCrossRefPubMed

12.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, et al. Baseline tumor 18FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+/HER2- breast cancer. J Nucl Med. 2015;56:824–31.CrossRefPubMed

13.

Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, et al. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer. 2013;109:1157–64.PubMedCentralCrossRefPubMed

14.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.CrossRefPubMed

15.

Groheux D, Hindié E, Giacchetti S, Hamy A-S, Berger F, Merlet P, et al. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer. 2014;50:1864–71.CrossRefPubMed

16.

Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:377–85.CrossRefPubMed

Title: Concerning pretreatment 18F-FDG PET/CT imaging in patients with large or locally advanced breast cancer
Authors: David Groheux
Elif Hindié
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3144-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2015

Survival outcomes in patients with cervical cancer after inclusion of PET/CT in staging procedures

Basal 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer

Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial

Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma

First determination of the heart-to-mediastinum ratio using cardiac dual isotope (123I-MIBG/99mTc-tetrofosmin) CZT imaging in patients with heart failure: the ADRECARD study

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer